| Anjarium Biosciences (Switzerland) |
Anjarium is researching and developing precision exosome therapeutics.
Their Hybridosome platform utilized nanotechnology and biochemistry
to increase the efficiency of exosome loading with therapeutic cargo.457 Anjarium is looking to use its exosome-based
therapy platform to treat cancers and rare genetic diseases. |
| Aruna Bio (USA) |
Aruna Bio is transforming
treatment for neurological and neurodegenerative
diseases. They utilize neural exosomes derived from neural stem cells
that have CNS specificity and the ability to cross the BBB. Their
candidate AB126 shows high uptake in the cerebellum and basal ganglia
showing treatment potential for diseases such as stroke and neurodegenerative
diseases.245 Their pipeline shows that
AB126 can be loaded with different cargos including siRNA, ASO, progranulin,
and tripeptidyl-peptidase 1.458
|
| Capricor (USA) |
Capricor is developing multiple exosome platforms including
cardiosphere-derived cell exosomes (CDC exosomes), engineered exosomes,
and an exosome-based vaccine. They are currently researching the use
of CDC exosomes for the treatment of Duchenne muscular dystrophy and
engineered exosomes for RNA and protein delivery in trauma-related
injuries and conditions in collaboration with the U.S. Army Institute of Surgical Research. They are also in preclinical
trials for an exosome-based multivalent vaccine for COVID-19 and other infectious diseases.459
|
| Carmine Therapeutics
(USA) |
Carmine Therapeutics utilizes red blood cell exosomes.460 Their Red Cell EV Gene Therapy (REGENT) platform
will be used to generate a pipeline of therapies for treatment of a wide
range of diseases.461
|
| EV Therapeutics (USA) |
EV Therapeutics is developing
modified exosomes (mEVs) (miR-424i and miR-424 KO) in combination with an immune checkpoint
inhibitor for treatment
of metastatic colorectal cancer and other GI cancers.462 mTEV is a CD-28–CD80/86 costimulatory pathway technology
platform that functions in combination with checkpoint inhibitors
to enhance T-cell immunomodulation
to prevent solid tumor cancer recurrence.463
|
| Evora BioSciences (France) |
The EVOGEX therapeutic platform was developed by Evora. Their
lead product EVOGEX-Digest aims to
treat digestive fistula and improve patient outcomes.464
|
| Evox (UK) |
Evox is an exosomal therapeutic
company using its DeliverEX
platform to deliver proteins and nucleic acids to treat a variety of rare diseases. Their internal program
is researching rare metabolic disorders. They have partnered with
Takeda to treat lysosomal storage disease and other undisclosed rare
diseases. Evox has also recently partnered with Lilly to research
neurological treatment.465
|
| Exocel Bio (USA) |
Exocel utilizes placental MSC-derived
exosomes for both skincare
and hair care. Their products include the Evovex line called Evovex
Restore, Evovex Revive, Evovex Renew, and Evovex Reveal.466 These products are used in conjunction with
facial and scalp microneedling and energy-based aesthetic device treatments
to enhance results and improve recovery time.467
|
| ExoCoBio (Republic of Korea) |
ExoCoBio is focusing its research on stem-cell-derived exosomes
to create both therapeutic and cosmetic products. They have developed
ExoSCRT Exosome for the treatment of atopic dermatitis,468 irritable bowel syndrome, acute kidney injury,
and alopecia.469 An immune-oncology drug
based on exosomes derived from immune cells is also in their pipeline. |
| Exogenus Therapeutics (Portugal) |
Exogenus’s
lead candidate Exo-101 is produced
from umbilical cord blood mononuclear cells. It has
been shown to have regenerative, anti-inflammatory, and immunomodulatory properties. Exo-101 is being investigated for treatment in inflammatory skin diseases
such as psoriasis, inflammatory lung disorders such as COVID-19 ARDS,470 and
chronic wound healing.471
|
| Florica Therapeutics (USA) |
Florica Therapeutics
aims to use hypothalamus stem-cell-derived
exosome therapeutics to increase lifespan and deter neurological diseases
of aging.472
|
| Ilias
Biologics (South Korea) |
Ilias developed the platform
EXPLOR that allows the loading
of proteins into exosomes in a more
controlled manner than conventional passive loading.473 Ilias’ lead compound ILB-202 consists of an exosome loaded with an anti-inflammatory protein super-repressor IkB targeting both acute and chronic inflammatory
diseases. This lowers the risk of an off-target effect by targeting
core inflammation signals.474
|
| Innocan Pharma (Israel) |
Innocan is a pharmaceutical
company researching cannabidiol (CBD) drugs and enhancing their targeting
due to its low bioavailability. Innocan is researching with Tel Aviv
University the development of CBD-loaded exosomes to target inflammatory
diseases and central nervous system diseases.475
|
| Kimera Laboratories (USA) |
Kimera specializes in the use of perinatal MSC-derived exosome
products for both cosmetics and scientific research.476 Their cosmetic products are XoGlo, XOGloPro, and Vive.
They also produce a veterinarian wound
healing agent called Equisome HC.477
|
| MDimune (Republic of Korea) |
MDimmune developed a platform
technology called BioDrone that uses cell-derived vesicles for targeted
drug delivery.478 Their internal pipeline
includes treatment for chronic obstructive pulmonary disease (COPD)
and an undisclosed rare disease with therapeutics BDR-231 and BDR-331, respectively. They have
partnered with Ildong, Kainos Medicine, and NeoCura for the treatment
of cancer using various mRNAs and small molecules for cargo for therapeutic
products BDR-165, BDR-166, and BDR-167. They are also partnered
with Reyon for a vaccine with therapeutic BDR-761 and treatment of an undisclosed rare disease
with therapeutic BDR-762 using mRNA
as cargo.479
|
| OmniSpirant
(Ireland) |
OmniSpirant’s platform technology is
based on inhalation
and is very efficient at delivering cargos to treat respiratory diseases.
The mucus penetrating exosomes will be used to develop a regenerative gene therapy for cystic fibrosis and
other respiratory diseases.480
|
| Regen Suppliers (USA) |
Regen Suppliers developed
an exosome product called ReBellaXO,
derived from umbilical stem cell tissue and Wharton’s jelly
used for regenerative cosmetic procedures involving facial, hair,
and sexual rejuvenation.481
|
| Xollent (USA) |
Xollent is advancing a diversified
pipeline of therapeutics including exosome therapeutics treating myocardial
infarction through an intravenous patch, alopecia through a spray,
and skin aging through a needle-free
injection.482
|
